Huijts, Charlotte M.
Werter, Inge M.
Lougheed, Sinéad M.
Goedegebuure, Ruben S.
van Herpen, Carla M.
Hamberg, Paul
Tascilar, Metin
Haanen, John B.
Verheul, Henk M.
de Gruijl, Tanja D.
van der Vliet, Hans J.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
https://doi.org/10.1007/s00262-018-2248-3
Funding for this research was provided by:
KWF Kankerbestrijding (VU 2011-5144)
Novartis
Article History
Received: 13 February 2018
Accepted: 19 September 2018
First Online: 9 November 2018
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: ClinicalTrials.gov Identifier NCT01462214, Netherlands Trial Register number NTR3085. The study was conducted in accordance with the Declaration of Helsinki and consistent with International Conference on Harmonization (ICH) Guidelines for Good Clinical Practice. The Medical Ethical Committee of the VU University Medical Center, Amsterdam, the Netherlands and the Central Committee on Research Involving Human Subjects (CCMO) approved the study protocol.
: All patients gave written informed consent.